LONDON (Reuters Health) Jul 04 –
Compared with paroxetine, nefazodone improves sleep disturbances during early treatment of patients with moderate-to-severe depression, according to the results of a randomized trial sponsored by Bristol-Myers Squibb Pharmaceuticals.
Dr. David J. Nutt from the University of Bristol in the UK and colleagues randomly assigned 40 depressed patients to receive 20 mg/day to 40 mg/day paroxetine or 400 mg/day to 600 mg/day nefazodone for 8 weeks. All of the subjects had disturbed sleep at baseline.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!